Informed Momentum Co LLC Invests $559,000 in Senseonics Holdings, Inc. (NYSE:SENS)

Key Points

• Informed Momentum Co LLC acquired 852,215 shares of Senseonics Holdings, Inc., valued at approximately $559,000, making up 0.13% of the company's total shares.
• A number of analysts have set a consensus rating of "Buy" for Senseonics, with an average target price of $1.55, highlighting positive market sentiment.
• Senseonics specializes in continuous glucose monitoring systems for diabetes management, reflecting its focus on medical technology innovations.

Informed Momentum Co LLC purchased a new stake in Senseonics Holdings, Inc. (NYSE:SENS - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 852,215 shares of the company's stock, valued at approximately $559,000. Informed Momentum Co LLC owned about 0.13% of Senseonics at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in SENS. IFP Advisors Inc boosted its position in shares of Senseonics by 120.9% during the 1st quarter. IFP Advisors Inc now owns 47,500 shares of the company's stock valued at $31,000 after purchasing an additional 26,000 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Senseonics during the 4th quarter valued at about $26,000. Smith Salley Wealth Management bought a new stake in shares of Senseonics during the 1st quarter valued at about $36,000. Two Sigma Investments LP bought a new stake in shares of Senseonics during the 4th quarter valued at about $36,000. Finally, Northern Trust Corp boosted its position in shares of Senseonics by 11.2% during the 4th quarter. Northern Trust Corp now owns 1,194,960 shares of the company's stock valued at $625,000 after purchasing an additional 120,441 shares in the last quarter. Institutional investors own 12.36% of the company's stock.

Senseonics Stock Performance

NYSE:SENS traded down $0.01 during trading hours on Friday, reaching $0.47. The stock had a trading volume of 3,022,566 shares, compared to its average volume of 8,269,783. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The stock has a 50 day simple moving average of $0.51 and a 200 day simple moving average of $0.64. Senseonics Holdings, Inc. has a 12-month low of $0.25 and a 12-month high of $1.40. The stock has a market cap of $385.02 million, a P/E ratio of -3.64 and a beta of 0.88.

Wall Street Analysts Forecast Growth

SENS has been the topic of several research analyst reports. Lake Street Capital upgraded Senseonics to a "strong-buy" rating in a research report on Thursday, July 17th. TD Cowen started coverage on Senseonics in a research note on Tuesday, July 15th. They issued a "buy" rating and a $1.25 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $1.40 price objective (up previously from $1.10) on shares of Senseonics in a research note on Tuesday, July 8th. Finally, Wall Street Zen raised Senseonics to a "sell" rating in a research note on Monday, May 12th. One investment analyst has rated the stock with a sell rating, two have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $1.55.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.